VA
ANIP icon

Vident Advisory’s ANI Pharmaceuticals ANIP Stock Holding History

Vident Advisory’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$409K Hold
4,935
– – ﹤0.01% 1467
2026
Q1 		$380K Buy
+4,935
New +$385K ﹤0.01% 1385

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's ANIP Position: Q2 2026 in Review

Vident Advisory held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 4,935 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Vident Advisory first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Vident Advisory held 4,935 shares of ANI Pharmaceuticals worth $409K as of Q2 2026.
  • Vident Advisory left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1467 holding.
  • Vident Advisory first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.